| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Journal of Clinical Endocrinology & Metabolism, Vol 80, 1799-1803, Copyright © 1995 by Endocrine Society
ARTICLES |
GJ Molijn, JJ Spek, JC van Uffelen, FH de Jong, AO Brinkmann, HA Bruining, SW Lamberts and JW Koper
Department of Medicine III, Erasmus University Rotterdam, The Netherlands.
In view of the immunosuppressive action of glucocorticoids (GCs), the activation of the hypothalamo-pituitary-adrenal axis in patients with sepsis or septic shock is paradoxical. At the same time, administration of GCs to these patients is not clearly beneficial. We investigated the role of GCs in severe illness by measuring the sensitivity of peripheral blood mononuclear leukocytes to GCs in a mitogen-stimulated lymphocyte proliferation assay. In addition, we studied the role of interleukin-2 and several other cytokines in this system. Cells from patients with sepsis or septic shock (n = 15) were more sensitive to the antiproliferative action of GCs than were cells from normal controls (IC50 6.7 +/- 2.1 nmol/L for patients vs. 19.5 +/- 2.5 nmol/L for controls; P < 0.01). This increased sensitivity of the peripheral mononuclear cells to dexamethasone during the period of sepsis normalized during the ensuing period of clinical recovery of these patients. Dexamethasone inhibited the production of interleukin-2 in the mitogen-stimulated cells. Addition of interleukin-2 antagonized the suppressive effects of dexamethasone in a dose-dependent manner, both in cells from controls and in cells from patients with sepsis. To a lesser extent, the combination of interleukin-1, interleukin-6, and tumor necrosis factor-alpha also counteracted the effects of dexamethasone. In conclusion, our results suggest that not only the activity of the hypothalamo-pituitary-adrenal axis but also the sensitivity to GCs is regulated during sepsis and septic shock. Generally there is an increased sensitivity to GCs, which might help to protect the organism as a whole through supportive effects on metabolism and vasculature. This hypersensitivity is counteracted, possibly at the site of inflammation, by high local concentrations of cytokines. This would enable an adequate local response of the immune system in the presence of elevated cortisol levels. In view of the increased sensitivity of peripheral leukocytes to GCs, treatment of these patients with high doses of GCs may not be beneficial or may even be harmful.
This article has been cited by other articles:
![]() |
M. S. Cooper and P. M. Stewart Adrenal Insufficiency in Critical Illness J Intensive Care Med, November 1, 2007; 22(6): 348 - 362. [Abstract] [PDF] |
||||
![]() |
B. M. Arafah Hypothalamic Pituitary Adrenal Function during Critical Illness: Limitations of Current Assessment Methods J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3725 - 3745. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Russcher, P. Smit, E. L. T. van den Akker, E. F. C. van Rossum, A. O. Brinkmann, F. H. de Jong, S. W. J. Lamberts, and J. W. Koper Two Polymorphisms in the Glucocorticoid Receptor Gene Directly Affect Glucocorticoid-Regulated Gene Expression J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5804 - 5810. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Smit, H. Russcher, F. H. de Jong, A. O. Brinkmann, S. W. J. Lamberts, and J. W. Koper Differential Regulation of Synthetic Glucocorticoids on Gene Expression Levels of Glucocorticoid-Induced Leucine Zipper and Interleukin-2 J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2994 - 3000. [Abstract] [Full Text] [PDF] |
||||
![]() |
G U. MEDURI and C. R. YATES Systemic Inflammation-Associated Glucocorticoid Resistance and Outcome of ARDS Ann. N.Y. Acad. Sci., June 1, 2004; 1024(1): 24 - 53. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. H. Hamrahian, T. S. Oseni, and B. M. Arafah Measurements of Serum Free Cortisol in Critically Ill Patients N. Engl. J. Med., April 15, 2004; 350(16): 1629 - 1638. [Abstract] [Full Text] [PDF] |
||||
![]() |
G.U. Meduri, P. Carratu, and A.X. Freire Evidence of biological efficacy for prolonged glucocorticoid treatment in patients with unresolving ARDS Eur. Respir. J., August 1, 2003; 22(42_suppl): 57s - 64s. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. H. Wirtz, R. von Kanel, P. Schnorpfeil, U. Ehlert, K. Frey, and J. E. Fischer Reduced Glucocorticoid Sensitivity of Monocyte Interleukin-6 Production in Male Industrial Employees who are Vitally Exhausted Psychosom Med, July 1, 2003; 65(4): 672 - 678. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Duclos, C. Gouarne, and D. Bonnemaison Acute and chronic effects of exercise on tissue sensitivity to glucocorticoids J Appl Physiol, March 1, 2003; 94(3): 869 - 875. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Cooper and P. M. Stewart Corticosteroid Insufficiency in Acutely Ill Patients N. Engl. J. Med., February 20, 2003; 348(8): 727 - 734. [Full Text] [PDF] |
||||
![]() |
A. Beishuizen and L. G. Thijs Review: Endotoxin and the hypothalamo-pituitary-adrenal (HPA) axis Innate Immunity, February 1, 2003; 9(1): 3 - 24. [Abstract] [PDF] |
||||
![]() |
H. Vermeer, B. I. Hendriks-Stegeman, B. van der Burg, S. C. van Buul-Offers, and M. Jansen Glucocorticoid-Induced Increase in Lymphocytic FKBP51 Messenger Ribonucleic Acid Expression: A Potential Marker for Glucocorticoid Sensitivity, Potency, and Bioavailability J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 277 - 284. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Annane, V. Sebille, C. Charpentier, P.-E. Bollaert, B. Francois, J.-M. Korach, G. Capellier, Y. Cohen, E. Azoulay, G. Troche, et al. Effect of Treatment With Low Doses of Hydrocortisone and Fludrocortisone on Mortality in Patients With Septic Shock JAMA, August 21, 2002; 288(7): 862 - 871. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. U. Meduri, E. A. Tolley, G. P. Chrousos, and F. Stentz Prolonged Methylprednisolone Treatment Suppresses Systemic Inflammation in Patients with Unresolving Acute Respiratory Distress Syndrome . Evidence for Inadequate Endogenous Glucocorticoid Secretion and Inflammation-induced Immune Cell Resistance to Glucocorticoids Am. J. Respir. Crit. Care Med., April 1, 2002; 165(7): 983 - 991. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Annane Replacement therapy with hydrocortisone in catecholamine-dependent septic shock Innate Immunity, August 1, 2001; 7(4): 305 - 309. [Abstract] [PDF] |
||||
![]() |
M. Ebrecht, A. Buske-Kirschbaum, D. Hellhammer, S. Kern, N. Rohleder, B. Walker, and C. Kirschbaum Tissue Specificity of Glucocorticoid Sensitivity in Healthy Adults J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3733 - 3739. [Abstract] [Full Text] |
||||
![]() |
T.M. O'CONNOR, D.J. O'HALLORAN, and F. SHANAHAN The stress response and the hypothalamic-pituitary-adrenal axis: from molecule to melancholia QJM, June 1, 2000; 93(6): 323 - 333. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. A. T. M. Huizenga, P. de Lange, J. W. Koper, W. W. de Herder, R. Abs, J. H. L. M. v. Kasteren, F. H. de Jong, and S. W. J. Lamberts Five Patients with Biochemical and/or Clinical Generalized Glucocorticoid Resistance without Alterations in the Glucocorticoid Receptor Gene J. Clin. Endocrinol. Metab., May 1, 2000; 85(5): 2076 - 2081. [Abstract] [Full Text] |
||||
![]() |
M. Panarelli, C. D. Holloway, R. Fraser, J. M. C. Connell, M. C. Ingram, N. H. Anderson, and C. J. Kenyon Glucocorticoid Receptor Polymorphism, Skin Vasoconstriction, and Other Metabolic Intermediate Phenotypes in Normal Human Subjects J. Clin. Endocrinol. Metab., June 1, 1998; 83(6): 1846 - 1852. [Abstract] [Full Text] |
||||
![]() |
S. F. Witchel, P. A. Lee, M. Suda-Hartman, M. Trucco, and E. P. Hoffman Evidence for a Heterozygote Advantage in Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2097 - 2101. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |